168 related articles for article (PubMed ID: 21601882)
1. CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the β1-integrin signaling.
Hongo K; Tanaka J; Tsuno NH; Kawai K; Nishikawa T; Shuno Y; Sasaki K; Kaneko M; Hiyoshi M; Sunami E; Kitayama J; Takahashi K; Nagawa H
J Surg Res; 2012 Jun; 175(2):278-88. PubMed ID: 21601882
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of CD133 enhances chemoresistance to 5-fluorouracil by activating the PI3K/Akt/p70S6K pathway in gastric cancer cells.
Zhu Y; Yu J; Wang S; Lu R; Wu J; Jiang B
Oncol Rep; 2014 Dec; 32(6):2437-44. PubMed ID: 25230779
[TBL] [Abstract][Full Text] [Related]
3. CD133 and CD133-regulated nucleophosmin linked to 5-fluorouracil susceptibility in human colon cancer cell line SW620.
Kim KH; Yoo BC; Kim WK; Hong JP; Kim K; Song EY; Lee JY; Cho JY; Ku JL
Electrophoresis; 2014 Feb; 35(4):522-32. PubMed ID: 24339132
[TBL] [Abstract][Full Text] [Related]
4. Chemoresistance of CD133(+) colon cancer may be related with increased survivin expression.
Lee MR; Ji SY; Mia-Jan K; Cho MY
Biochem Biophys Res Commun; 2015 Jul; 463(3):229-34. PubMed ID: 26002465
[TBL] [Abstract][Full Text] [Related]
5. 5-Fluorouracil upregulates the activity of Wnt signaling pathway in CD133-positive colon cancer stem-like cells.
Deng YH; Pu XX; Huang MJ; Xiao J; Zhou JM; Lin TY; Lin EH
Chin J Cancer; 2010 Sep; 29(9):810-5. PubMed ID: 20800023
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
[TBL] [Abstract][Full Text] [Related]
7. CD133+CD24lo defines a 5-Fluorouracil-resistant colon cancer stem cell-like phenotype.
Paschall AV; Yang D; Lu C; Redd PS; Choi JH; Heaton CM; Lee JR; Nayak-Kapoor A; Liu K
Oncotarget; 2016 Nov; 7(48):78698-78712. PubMed ID: 27659530
[TBL] [Abstract][Full Text] [Related]
8. CD133 expression predicts for non-response to chemotherapy in colorectal cancer.
Ong CW; Kim LG; Kong HH; Low LY; Iacopetta B; Soong R; Salto-Tellez M
Mod Pathol; 2010 Mar; 23(3):450-7. PubMed ID: 20081809
[TBL] [Abstract][Full Text] [Related]
9. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
[TBL] [Abstract][Full Text] [Related]
10. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells.
Tseng LM; Huang PI; Chen YR; Chen YC; Chou YC; Chen YW; Chang YL; Hsu HS; Lan YT; Chen KH; Chi CW; Chiou SH; Yang DM; Lee CH
J Pharmacol Exp Ther; 2012 May; 341(2):410-23. PubMed ID: 22328572
[TBL] [Abstract][Full Text] [Related]
11. Colorectal cancer stem cell and chemoresistant colorectal cancer cell phenotypes and increased sensitivity to Notch pathway inhibitor.
Huang R; Wang G; Song Y; Tang Q; You Q; Liu Z; Chen Y; Zhang Q; Li J; Muhammand S; Wang X
Mol Med Rep; 2015 Aug; 12(2):2417-24. PubMed ID: 25936357
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer.
Kemper K; Versloot M; Cameron K; Colak S; de Sousa e Melo F; de Jong JH; Bleackley J; Vermeulen L; Versteeg R; Koster J; Medema JP
Clin Cancer Res; 2012 Jun; 18(11):3132-41. PubMed ID: 22496204
[TBL] [Abstract][Full Text] [Related]
13. A gene signature distinguishing CD133hi from CD133- colorectal cancer cells: essential role for EGR1 and downstream factors.
Ernst A; Aigner M; Nakata S; Engel F; Schlotter M; Kloor M; Brand K; Schmitt S; Steinert G; Rahbari N; Koch M; Radlwimmer B; Weitz J; Lichter P
Pathology; 2011 Apr; 43(3):220-7. PubMed ID: 21436631
[TBL] [Abstract][Full Text] [Related]
14. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of CD133(+) human colon cancer SW620 cells.
Kawamoto H; Yuasa T; Kubota Y; Seita M; Sasamoto H; Shahid JM; Hayashi T; Nakahara H; Hassan R; Iwamuro M; Kondo E; Nakaji S; Tanaka N; Kobayashi N
Cell Transplant; 2010; 19(6):857-64. PubMed ID: 20587144
[TBL] [Abstract][Full Text] [Related]
16. In vivo 5FU-exposed human medullary thyroid carcinoma cells contain a chemoresistant CD133+ tumor-initiating cell subset.
Kucerova L; Feketeova L; Kozovska Z; Poturnajova M; Matuskova M; Nencka R; Babal P
Thyroid; 2014 Mar; 24(3):520-32. PubMed ID: 24073856
[TBL] [Abstract][Full Text] [Related]
17. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.
Tang KH; Ma S; Lee TK; Chan YP; Kwan PS; Tong CM; Ng IO; Man K; To KF; Lai PB; Lo CM; Guan XY; Chan KW
Hepatology; 2012 Mar; 55(3):807-20. PubMed ID: 21994122
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD133 antigen in cancer.
Ferrandina G; Petrillo M; Bonanno G; Scambia G
Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986
[TBL] [Abstract][Full Text] [Related]
19. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line.
Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J
Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast-Derived Exosomes Contribute to Chemoresistance through Priming Cancer Stem Cells in Colorectal Cancer.
Hu Y; Yan C; Mu L; Huang K; Li X; Tao D; Wu Y; Qin J
PLoS One; 2015; 10(5):e0125625. PubMed ID: 25938772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
